Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain
CompletedNCT05674240
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.
Study details
- Official title
- Intrathecal Targeted Drug Delivery for Cancer Associated Pain
- Conditions
- Cancer Pain
- Chronic Pain
- Cancer Associated Pain
- Neuropathic Pain
- Interventions
- Device: Intrathecal Targeted Drug Delivery
- Combination product: Conservative medical management
- Sponsor
- Wake Forest University Health Sciences
- Start date
- 2022-12-06
- Primary completion
- 2026-03-20
- Sex
- All
- Age range
- from 21 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age of 21 and older * Uncontrolled cancer-associated pain (pain score of \>5 on NRS) despite oral use of 60 mg/d morphine equivalent a week prior to screening * Adverse side effects from long term opioid use defined as limiting or severely affecting patient's day to day function * Life expectancy of \> 3 months Exclusion Criteria: * Active infections * Controlled pain without adverse side effects that are limiting day to day function * Mechanical barriers * Obstruction of Cerebrospinal Fluid (CSF)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05674240